Free Trial
ASX:HLS

Healius (HLS) Stock Price, News & Analysis

Healius logo

About Healius Stock (ASX:HLS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.33 million shs
Average Volume
N/A
Market Capitalization
A$1.01 billion
P/E Ratio
N/A
Dividend Yield
4.46%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive HLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Healius and its competitors with MarketBeat's FREE daily newsletter.

HLS Stock News Headlines

Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
Spheria Reduces Stake in Healius Limited
See More Headlines

HLS Stock Analysis - Frequently Asked Questions

Healius Limited (ASX:HLS) issued its quarterly earnings results on Friday, February, 15th. The company reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.09 by $0.06. Healius had a negative trailing twelve-month return on equity of 61.77% and a negative net margin of 36.98%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Healius investors own include bluebird bio (BLUE), Argonaut Gold (AR), Athene (ATH), BELLUS Health (BLU), Esperion Therapeutics (ESPR), Fortress Biotech (FBIO) and Forte Biosciences (FBRX).

Company Calendar

Last Earnings
2/15/2019
Ex-Dividend for 5/22 Dividend
5/08/2025
Record date for 5/22 Dividend
5/22/2025
Dividend Payable
5/22/2025
Today
7/01/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
ASX:HLS
CIK
N/A
Fax
N/A
Employees
10,500
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
-0.94
Net Income
-A$636 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
A$1.75 billion
Price / Cash Flow
12.26
Book Value
A$0.88 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
A$1.01 billion
Optionable
Not Optionable
Beta
0.73
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (ASX:HLS) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners